DUBLIN--(BUSINESS WIRE)--The "Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)" report has been added to ResearchAndMarkets.com's offering.
Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022) provides an extensive research and detailed analysis of the present market along with future outlook.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
The report profiles the key players of the market including Pfizer Inc., Sanofi S.A., Shire Plc and Protalix BioTherapeutics, Inc.
Key Topics Covered:
1. Market Overview
2. Global LSD Market Analysis
3. Market Dynamics
4. Competitive Landscape
5. Company Profiles
- Pfizer Inc.
- Protalix BioTherapeutics, Inc.
- Sanofi S.A.
- Shire Plc
For more information about this report visit https://www.researchandmarkets.com/research/7fc3ft/global_lysosomal?w=4